Key result
Symptom-limited cardiopulmonary exercise testing significantly enhanced platelet aggregation in patients with stable coronary artery disease on aspirin (from 72.9% to 80.9%) or dual antiplatelet therapy (from 43.0% to 50.1%).
Why the study?
Acute exercise stimulation may increase thrombotic risk through platelet activation, but studies on the effects of cardiac rehabilitation on platelet function have been sparse.
Does symptom-limited cardiopulmonary exercise testing increase platelet activation and aggregation in patients with stable coronary artery disease on antiplatelet therapy?
Observational (n=28)
No
Does symptom-limited cardiopulmonary exercise testing increase platelet activation and aggregation in patients with stable coronary artery disease on antiplatelet therapy?
Symptom-limited cardiopulmonary exercise testing safely increases platelet aggregation in stable CAD patients on antiplatelet therapy, primarily driven by an exercise-induced increase in platelet count rather than direct single platelet activation.
Alerts clinicians to transient thrombotic risk during CPET despite antiplatelets; extends RCT evidence on platelet reactivity under exercise stress.
BACKGROUND: Cardiac rehabilitation reduces mortality and morbidity rate of patients with coronary artery diseases (CAD); however, acute exercise stimulation may also increase the thrombotic risk through platelet activation. Studies on the effects of cardiac rehabilitation on platelet function have been sparse. METHODS: A total of 28 patients (24 men and 4 women; average age = 54.6 ± 8 years old) with stable CAD were enrolled in this study and divided into Aspirin-treated (n = 11; Aspirin group) and dual-antiplatelet-treated group (DAPT group; n = 17). Symptom-limited cardiopulmonary exercise test (CPET) with a cycle ergometer was performed on all the patients. Before and after CPET, platelet function was evaluated using light transmission aggregometry and whole blood flow cytometry. RESULTS: ) was 19.3 ± 3 ml/(kg min). Prior to CPET, platelet aggregation was significantly suppressed in DAPT group compared to Aspirin group (43.0 ± 21.5 vs. 72.9 ± 7.5, p < 0.001). CPET promoted platelet aggregation in Aspirin group (72.9 ± 7.5 vs. 80.9 ± 7.6, p = 0.005) and DAPT group (43.0 ± 21.5 vs. 50.1 ± 20.9, p = 0.010), and platelet count was increased in Aspirin (210.9 ± 54.6 vs. 227.5 ± 58.1, p = 0.001) and DAPT group (217.5 ± 63.8 vs. 229.7 ± 63.7, p = 0.001). However, the expression levels of CD62p and PAC-1 were not affected by CPET in both groups. CONCLUSION: Symptom-limited CPET enhanced platelet aggregation in patients with CAD despite treatment with antiplatelet, mainly via platelet count augmentation, but not through single platelet activation. TRIAL REGISTRATION: Effects of high intensity interval training versus moderate intensity continue training in cardiac rehabilitation on platelet function of patients with coronary heart diseases: a exploratory randomized controlled trial. ChiCTR-INR-17010717. Registered 23 February 2017, https://www.chictr.org.cn/edit.aspx?pid=18206&htm=4 .
No takes yet. Share an insight, caveat, or question.
Yin et al. (2022) conducted an observational in Stable coronary artery disease (n=28). Cardiopulmonary exercise test (CPET) vs. Baseline (before CPET) was evaluated on Platelet aggregation (%) in Aspirin group (p=0.005). Symptom-limited cardiopulmonary exercise testing significantly enhanced platelet aggregation in patients with stable coronary artery disease on aspirin (from 72.9% to 80.9%) or dual antiplatelet therapy (from 43.0% to 50.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: